American journal of translational research · 2024
Analysis of the efficacy of lactulose combined with polyethylene glycol in the treatment of functional constipation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Jing, Liu Ning, Yang Yuanhong, Zhang Yafeng
Аннотация
OBJECTIVES: This study focuses on analyzing the efficacy of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of functional constipation (FC).
METHODS: A total of 125 FC patients were selected, with 60 cases in a control group, who were treated with lactulose oral solution alone, and 65 cases in a research group, who were treated with lactulose oral solution combined with Macrogol 4000 Powder. The two groups were analyzed and compared in terms of efficacy, symptom recovery, Bristol Stool Form Scale (BSFS) and Wexner Constipation Scale (WCS) scores, adverse effects, serum indices, and Patient Assessment of Constipation Quality of Life (PAC-QOL). Univariate and multivariate analyses were performed to identify risk factors affecting the efficacy.
RESULTS: The total response rate of treatment in the research group was higher than that in the control group, and the symptom recovery was significantly better in the research group. In addition, the research group showed markedly elevated BSFS scores and reduced WCS scores after treatment as compared to the control group. Furthermore, significantly better improvements in various serum indices were determined in the research group. There was no remarkable difference in the incidence of total adverse reactions between groups. Finally, the course of disease, hypertension, diabetes, hyperlipidemia, and therapeutic method were identified to be factors affecting treatment efficacy in patients with FC.
CONCLUSIONS: The efficacy therapeutic of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of FC is promising.
METHODS: A total of 125 FC patients were selected, with 60 cases in a control group, who were treated with lactulose oral solution alone, and 65 cases in a research group, who were treated with lactulose oral solution combined with Macrogol 4000 Powder. The two groups were analyzed and compared in terms of efficacy, symptom recovery, Bristol Stool Form Scale (BSFS) and Wexner Constipation Scale (WCS) scores, adverse effects, serum indices, and Patient Assessment of Constipation Quality of Life (PAC-QOL). Univariate and multivariate analyses were performed to identify risk factors affecting the efficacy.
RESULTS: The total response rate of treatment in the research group was higher than that in the control group, and the symptom recovery was significantly better in the research group. In addition, the research group showed markedly elevated BSFS scores and reduced WCS scores after treatment as compared to the control group. Furthermore, significantly better improvements in various serum indices were determined in the research group. There was no remarkable difference in the incidence of total adverse reactions between groups. Finally, the course of disease, hypertension, diabetes, hyperlipidemia, and therapeutic method were identified to be factors affecting treatment efficacy in patients with FC.
CONCLUSIONS: The efficacy therapeutic of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of FC is promising.